Ambrx Biopharma (AMAM) SC 13G Ambrx Biopharma / D. E. SHAW & CO ownership change

Exhibit 3

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Ordinary shares, $0.0001 par value per share, of Ambrx Biopharma Inc., and that this Agreement be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, each of the undersigned hereby executes this Agreement as of this 16^th day of March, 2023.

D. E. Shaw Valence Portfolios, L.L.C.
By:	/s/ Nathan Thomas
	Nathan Thomas
	Authorized Signatory

D. E. Shaw & Co., L.L.C.
By:	/s/ Nathan Thomas
	Nathan Thomas
	Authorized Signatory

D. E. Shaw & Co., L.P.
By:	/s/ Nathan Thomas
	Nathan Thomas
	Chief Compliance Officer

David E. Shaw
By:	/s/ Nathan Thomas
	Nathan Thomas
	Attorney-in-Fact for David E. Shaw